Výsledky vyhledávání - "Edward K. Barnes"

High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium

Autor: Edward Arrowsmith, Dianna Shipley, James A. Reeves, David M. Waterhouse, Edward K. Barnes, John D. Hainsworth

Publikováno v: Clinical genitourinary cancer. 11(3)

Background The dose of bevacizumab necessary to optimally inhibit tumor angiogenesis in advanced renal cell carcinoma is unknown. In this phase II trial, we evaluated the efficacy and safety of 2 escalated doses of bevacizumab in patients with advanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cab24e96ed4a595d1d061e9708670a4
https://pubmed.ncbi.nlm.nih.gov/23684421

Zobrazit plný text záznamu

Adjuvant carboplatin, docetaxel, bevacizumab, and erlotinib versus chemotherapy alone in patients with resected non-small cell lung cancer: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)

Autor: John D. Hainsworth, David R. Spigel, James D. Peyton, Mathew John Joseph, Sang Y. Huh, Edward K. Barnes, David Michael Waterhouse, Raven Quinn, Victor G. Gian, Davey B. Daniel, F. A. Greco, Howard A. Burris, Christopher F. Lobo

Publikováno v: Journal of Clinical Oncology. 30:7035-7035

7035 Background: Adjuvant chemotherapy improves overall survival (OS) in patients (pts) with resected non small cell lung cancer (NSCLC). Bevacizumab and erlotinib improve survival in pts with advanced unresectable NSCLC. This randomized phase II mul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b5bd6408288e58d2ec8bc4850b3478c
https://doi.org/10.1200/jco.2012.30.15_suppl.7035

Zobrazit plný text záznamu

A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer

Autor: E. T. Lubiner, D. S. Thompson, J. D. Peyton, F. A. Greco, H. A. Burris, David R. Spigel, Dianna Shipley, Edward K. Barnes, John D. Hainsworth, Thomas Ervin

Publikováno v: Journal of Clinical Oncology. 28:7593-7593

7593 Background: Elderly patients (pts) (≥70 years old) account for >40% of pts diagnosed with non-small cell lung cancer (NSCLC). Pemetrexed/gemcitabine and pemetrexed/carboplatin are both active ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12cc029aa600389c893bc8cf25dac225
https://doi.org/10.1200/jco.2010.28.15_suppl.7593

Zobrazit plný text záznamu

Preoperative oxaliplatin (O), docetaxel (D), capecitabine (C), and concurrent radiation therapy (RT) for patients (pts) with localized esophageal cancer: A phase I/II trial of the Minnie Pearl Cancer Research Network

Autor: J. F. Patton, C. Farley, F. A. Greco, Dianna Shipley, H. A. Burris, A. A. Meluch, John D. Hainsworth, Denise A. Yardley, David R. Spigel, Edward K. Barnes

Publikováno v: Journal of Clinical Oncology. 24:4058-4058

4058 Background: Preoperative chemoradiotherapy improves outcomes for pts with resectable esophageal cancer compared with surgery alone. We previously reported a 41% 3-year progression-free survival (PFS) with preoperative paclitaxel/carboplatin/5FU/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db4e6ef7278ccfb3862d7eb9e29802d2
https://doi.org/10.1200/jco.2006.24.18_suppl.4058

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání